(Q35649646)

9 August 2017

0 references

Severe hepatic complications of antituberculous therapy (English)

1 reference

9 August 2017

M O Turner

1

1 reference

PubMed ID

22346382

9 August 2017

R K Elwood

series ordinal

2

1 reference

PubMed ID

22346382

9 August 2017

language of work or name

English

0 references

publication date

1 March 1999

1 reference

Canadian Journal of Infectious Diseases & Medical Microbiology

9 August 2017

1 reference

9 August 2017

10

1 reference

9 August 2017

2

1 reference

9 August 2017

167-169

1 reference

Creative Commons Attribution 4.0 International

9 August 2017

start time

1 January 1999

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Liver injury during antituberculosis treatment: an 11-year study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250713

Hepatotoxicity of antituberculosis drugs

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250713

Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250713

Anti-tuberculous therapy and acute liver failure.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250713

Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250713

Anti-tuberculosis medication and the liver: dangers and recommendations in management

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250713

Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250713

Toxic hepatitis with isoniazid and rifampin. A meta-analysis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250713

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3250713

Chemotherapy and management of tuberculosis in the United Kingdom: recommendations of the Joint Tuberculosis Committee of the British Thoracic Society

12 July 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22346382

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Drug-induced hepatotoxicity

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22346382

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22346382

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1155/1999/342613

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

PubMed ID

22346382